ANNX

Annexon is a clinical-stage biopharma with zero revenue across all five reported fiscal years, financing the business entirely by burning equity. FY2025 net loss widened 49.6% to -$207M and operating cash flow deteriorated 57.9% to -$186M, driven by a 54.6% surge in R&D to $185M as the company pushed tanruprubart (GBS) and vonaprument (geographic atrophy) toward registration. Accumulated deficit of -$917M and ROE of -97.7% underscore that this is a binary, catalyst-driven equity, not a business with intrinsic earnings power. Valuation in the traditional sense is meaningless here — there are no sales to anchor a multiple to.

What keeps this from being an outright avoid is the MD&A roadmap and a freshly recapitalized balance sheet. Cash & equivalents jumped 227.4% YoY to $162M, and current assets of $242M against just $42.6M of current liabilities give roughly a year of runway at the current burn — tight, but enough to reach the two named catalysts: a planned FDA BLA submission for tanruprubart in GBS in 2026 (MAA already filed with EMA in January 2026), and ARCHER II Phase 3 topline for vonaprument in GA in Q4 2026. Both programs carry regulatory tailwinds the filing flags explicitly — Fast Track + orphan designation for tanruprubart, PRIME designation and the EMA Product Development Coordinator Pilot for vonaprument — and the Phase 3 GBS data the MD&A cites (90% improvement by week 1, doubled rate of normal health at week 26) is non-trivial in an indication with no FDA-approved therapy.